HANGZHOU, China and SHAOXING, China, Nov. 18, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that the board of directors of the Company (the "Board") resolved to change ...
Resmetirom is the first FDA-approved drug for NASH with liver fibrosis, offering a new treatment option alongside lifestyle changes. Clinical trials demonstrated significant NASH resolution and ...
The recent Phase 3 (MAESTRO-NAFLD-1) study delivered extremely strong results. This month, Madrigal is expected to release the data for its Phase 3 (MAESTRO-NASH) trial. Depending on the results of ...
Phase III data from Gilead’s hepatitis D ‘cure’ and Madrigal’s NASH hopeful take center stage at ILC
New data confirming that Gilead Sciences Inc.’s Hepcludex (bulevirtide) effectively cures hepatitis delta virus (hepatitis D), one of the most severe viral infections of the liver, and favorable phase ...
LYON, France--(BUSINESS WIRE)--ENYO Pharma, a clinical stage biotech company developing innovative drug candidates, today announced completion of its phase Ib clinical trial evaluating the safety, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback